Brain Cancer News and Research RSS Feed - Brain Cancer News and Research

There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

A major claim of ObamaCare's political salesmen is that it will reduce U.S. health spending. The heart of this claim is the Accountable Care Organization, or ACO, but already evidence is accumulating that it isn't working. [More]
Discovery could prolong life of people living with glioblastoma

Discovery could prolong life of people living with glioblastoma

Researchers at the University of Calgary's Hotchkiss Brain Institute and Southern Alberta Cancer Research Institute have made a discovery that could prolong the life of people living with glioblastoma – the most aggressive type of brain cancer. Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I/II clinical trial as early as Spring 2015. [More]
Research finding offers new insights into the cause of glioblastoma

Research finding offers new insights into the cause of glioblastoma

Researchers at the University of California, San Diego School of Medicine have identified a new fusion protein found in approximately 15 percent of secondary glioblastomas or brain tumors. The finding offers new insights into the cause of this cancer and provides a therapeutic target for personalized oncologic care. [More]
Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Hubris is the greatest danger in wealthy countries -; a sort of smug assumption that advanced technologies and emergency-preparedness plans guarantee that Ebola and other germs will not spread. It was hubris that left Toronto's top hospitals battling SARS in 2003, long after the virus was conquered in poorer Vietnam. It was hubris that led the World Health Assembly in 2013 to cut the WHO's outbreak-response budget in favor of more programs to treat cancer and heart disease. [More]
Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

Walmart announced today that as of the beginning of next year it will be dropping health insurance for 30,000 employees who work less than 30 hours per week. Many liberals will react to the news by saying that it's just a profit-hungry corporation once again screwing over its employees. Conservatives are likely to say that this just shows what a mess Obamacare has created and why it should be repealed (Paul Waldman, 10/8). [More]
CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

Using an innovative algorithm that analyzes gene regulatory and signaling networks, Columbia University Medical Center researchers have found that loss of a gene called KLHL9 is the driving force behind the most aggressive form of glioblastoma, the most common form of brain cancer. [More]
VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai. [More]
CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors. [More]
Viewpoints: Relatively few face insurance cancellations; new doctor payment site is 'impenetrable'

Viewpoints: Relatively few face insurance cancellations; new doctor payment site is 'impenetrable'

People are starting to get letters telling them their health insurance plans have been canceled because of the Affordable Care Act. Because the letters will go out just before the midterm congressional elections, they are likely to get a lot of attention. There have been several stories this past week. But the people affected will represent only a small fraction of the population with health insurance (Margot Sanger-Katz, (10/6). [More]
CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy. [More]
FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer. [More]
Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center. [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]

Using handheld Raman scanner researchers completely removed brain tumors

Cancerous brain tumors are notorious for growing back despite surgical attempts to remove them - and for leading to a dire prognosis for patients. [More]
One-two punch designed to knock out most dangerous brain cancer

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer. [More]
TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma

TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma

SIn 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute. One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin. [More]
Researchers find why certain glioblastomas become drug resistance

Researchers find why certain glioblastomas become drug resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy. [More]
Researchers find more selective therapies for cancer

Researchers find more selective therapies for cancer

Thanks to important discoveries in basic and clinical research and technological advances, the fight against cancer has mobilized into a complex offensive spanning multiple fronts. [More]
New web-based program helps to determine deadly form of brain cancer

New web-based program helps to determine deadly form of brain cancer

A new web-based program developed by University of Kentucky Markey Cancer Center researchers will provide a simple, free way for healthcare providers to determine which brain tumor cases require testing for a genetic mutation. [More]
Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Injections of anaerobic bacteria can shrink tumors in rats, dogs and human

Deep within most tumors lie areas that remain untouched by chemotherapy and radiation. These troublesome spots lack the blood and oxygen needed for traditional therapies to work, but provide the perfect target for a new cancer treatment using bacteria that thrive in oxygen-poor conditions. [More]